SEC Tracker
Get the app
BIIB · XBRL financial data

Biogen financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (BIIB's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue2,386*2,2912,4652,4662,455*2,4312,6462,5352,279*2,4782,7362,804
Cost of goods and services sold618*542546639584*629605674496*661777748
Selling, general and administrative609*582554588680*573584595683*607710752
Other operating income (expense)—(94)(85)(15)—(68)(49)(34)—(20)(19)(137)
Interest income24*17201219*24323237*38259
Interest expense72*69616060*60736768*688288
Other income (expense)9*(2)(2)(1)34*(1)(3)16(37)*(1)311
Income tax expense (benefit)43*711156325*7110991(7)*583512
Net income (loss)250*393584389267*241635467(49)*32098(21)
Earnings per share, basic USD per share1.72*2.714.012.671.83*1.654.333.18(0.33)*2.170.66(0.14)
Earnings per share, diluted USD per share1.70*2.704.002.661.83*1.644.333.17(0.33)*2.150.66(0.14)
Weighted average shares, basic millions of shares145*145146146146*146147147147*147148148
Weighted average shares, diluted millions of shares147*146146146146*147147147148*148149148

Balance sheet

CSV

Fiscal quarters (BIIB's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents1,0501,0741,9091,6992,3752,5982,7593,8633,0093,3831,2851,304
Marketable securities0———0——9880790000
Marketable securities, non-current0———0———43246600
Accounts receivable1,664———1,405———1,342———
Inventory2,5272,5172,5062,4692,4612,2742,2742,2092,1681,9492,3842,224
Total current assets6,8596,7567,1096,8317,4577,6267,9688,9378,9749,1907,3067,584
Property and equipment, net3,3103,2753,2493,2113,1813,1323,0993,0763,0553,0182,9942,968
Right-of-use asset420428389380356346335331265251246176
Goodwill6,2196,2276,2276,4866,4796,4776,4936,4916,4916,4896,9916,993
Total assets26,84526,56826,80428,31328,04928,03328,33029,20829,44029,48332,08732,054
Accounts payable403387355423424392408413432359404430
Total current liabilities3,4343,2233,1085,4255,5295,2973,1843,2903,3492,9993,9173,898
Lease liability, non-current400407368357335323311305290273265109
Total liabilities12,04511,35510,91511,95411,33311,05410,69611,00011,18310,83113,23913,132
Retained earnings17,62818,02118,60518,99319,26019,50020,13520,60220,55320,87220,97020,949
Total stockholders' equity14,799———————————
Total liabilities and equity26,84526,56826,80428,31328,04928,03328,33029,20829,44029,48332,08732,054
Common shares outstanding (cover page) millions of shares145146146146146147147147147148148148

Cash flows

CSV

Fiscal quarters (BIIB's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)250*393584389267*241635467(49)*32098(21)
Stock-based compensation55*7371*73*75*8175*75*60*8477*82*
Depreciation and amortization140*148159*183*184*183194*202*200*204236*241*
Net cash from operating activities13*553626*936*761*259161*1,273*512*646449*641*
Purchases of property and equipment65*4634*35*39*3727*46*44*5141*40*
Net cash from investing activities(652)*(66)467*(1,181)*(19)*(47)(57)*(35)*(1,232)*(210)(3,839)*(222)*
Share repurchases0*———year only———————
Proceeds from long-term debt0*——0*0*——(0)*0*——0*
Repayments of long-term debt650*400250*0*0*01,750*0*0*——400*
Net cash from financing activities(646)*(440)(245)*(7)*8*(23)(12)*(130)*(137)*(44)1,296*(394)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Biogen1,3042,804641*147.8M— 10-QSep 30, 2026
Teva Pharmaceutical Industries4,0854,3952411.2B— 10-QSep 30, 2026
INSMED397524(36)*219.4M— 10-QSep 30, 2026
BeOne Medicines5,0981,705463*1.5B— 10-QJun 30, 2026
United Therapeutics1,803783314*42.9M— 10-QJun 30, 2026
Roivant Sciences1,2481.4(271)722.3M14.2 quarters 10-QJun 30, 2026
Neurocrine Biosciences6421,123395*101.2M— 10-QSep 30, 2026
Exelixis305659280*244.0M— 10-QOct 2, 2026
BIO-TECHNE265321*95*156.8M— 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.